BRD3308

Overview

BRD3308 is a highly selective HDAC3 inhibitor with an IC 50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 ( IC 50 of 1.26 μM) or HDAC2 ( IC 50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > HIV | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-19618
• CAS No.: 1550053-02-5
• Molecular Formula: C15H14FN3O2
• Molecular Weight: 287.29
• Purity: 98.34%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (7.24 mM); Clear solution
• Availability: In-stock

Source

Original product source